AbbVie/AstraZeneca CLL Combo Cuts Progression Risk by 35%
The FDA approved an all-oral, fixed-duration combination of venetoclax and acalabrutinib for previously untreated CLL patients, marking the first such regimen. AMPLIFY Phase 3 results showed 77% progression-free at three years versus 67% with chemotherapy, with a 35% reduction in risk of progression or death.
1. FDA Approves First All-Oral Fixed-Duration CLL Treatment
The FDA granted approval for the combination of venetoclax and acalabrutinib as the first all-oral, fixed-duration therapy for previously untreated chronic lymphocytic leukemia patients. This regimen offers a defined treatment period and the potential for treatment-free intervals, addressing a key limitation of continuous therapies.
2. AMPLIFY Phase 3 Trial Data
In the AMPLIFY study, 77% of patients receiving the combination were progression-free at three years compared to 67% on standard chemoimmunotherapy. Median progression-free survival was not reached in the combination arm versus 47.6 months for chemotherapy, while risk of progression or death fell by 35%.
3. Implications for AbbVie, AstraZeneca and CLL Care
This approval positions AbbVie and AstraZeneca to capture early-line CLL market share and potentially boost oncology revenues. The regimen’s oral, time-limited profile may set a new standard of care, prompting treatment guideline updates and competitive responses from other leukemia therapies.